Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Dopa-Responsive Dystonia Revisited
Arch Neurol 69:1558-1562, Tadic, V.,et al, 2012
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Clinicopath Conf, Dopamine-Responsive-Dystonia Caused by a Mutation in the GCH1 Gene
NEJM 355:831-839, Case 26-2006, 2006
Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Random, Placebo-Contr Study of Tolcapone in Pts with Fluctuating Parkinson Dis Trtd With Levodopa-Carbidopa
Arch Neurol 55:1089-1095, Adler,C.H.,et al, 1998
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Standard & Controlled-Release Levodopa/Carbidopa in Fluctuating Parkinson's Disease on a Protein Redistribution Diet
Arch Neurol 48:402-405, Karstaedt,P.J.,et al, 1991
Dopa Responsive Dystonia:A Treatable Condition Misdiagnosed as Cerebral Palsy
BMJ 298:1019-1020, Boyd,K.&Patterson,V., 1989
Bromocriptine in Parkinson Disease:Further Studies
Neurol 29:363-369, Lieberman,A.N.,et al, 1979
Comparative Effectiveness of Two Extracerebral DOPA Decarboxylase Inhibitors in Parkinson Disease
Neurol 28:964-968, Lieberman,A.,et al, 1978
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976